TheraRadar
← All Biomarkers

HER2-

2 drugs

Human Epidermal Growth Factor Receptor 2 Negative

Predictive biomarker for patient selection in 29 indications

Understanding HER2-

What it means: HER2- means the cancer does not overexpress HER2 protein. The tumor may still be hormone receptor positive (HR+).
Why it matters: HER2- patients do not benefit from traditional HER2 therapies but HER2-low (IHC 1+ or 2+/FISH-) may respond to T-DXd.
Testing: Tested via immunohistochemistry (IHC) showing 0 or 1+ staining, or 2+ with negative FISH.
2
Approved Drugs
29
Indications
2
Companies

HER2- is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 29 indications including Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence, Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine-based therapy, Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Explore the targeted therapies, indications, testing methods, and companies developing HER2- drugs below.

Search HER2- Clinical Trials

Search recruiting trials on ClinicalTrials.gov

Drugs Targeting HER2-

Drug Company Therapeutic Area
KEYTRUDA Merck Oncology
VERZENIO Eli Lilly Oncology

HER2- Indications

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine-based therapy Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting Melanoma Non-Small Cell Lung Cancer Malignant Pleural Mesothelioma Head and Neck Squamous Cell Cancer Classical Hodgkin Lymphoma Primary Mediastinal Large B-Cell Lymphoma Urothelial Cancer Microsatellite Instability-High Cancer Mismatch Repair Deficient Cancer Colorectal Cancer Gastric Cancer Gastroesophageal Junction Adenocarcinoma Esophageal Cancer Cervical Cancer Hepatocellular Carcinoma Biliary Tract Cancer Merkel Cell Carcinoma Renal Cell Carcinoma Endometrial Carcinoma Tumor Mutational Burden-High Cancer Cutaneous Squamous Cell Carcinoma Triple-Negative Breast Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Companies with HER2- Drugs

Eli Lilly Merck